Difficulties in the diagnosis and choice of treatment tactics for patients with atypical hemolytic uremic syndrome
In recent years, there has been a trend towards an increase in the incidence of atypical hemolytic uremic syndrome (aHUS) in the clinical practice of doctors of various specialties. Every year the number of nosologies in which the phenomenon of TMA is recorded is steadily growing. The goals of aHUS therapy are the inhibition of uncontrolled complement activation, the relief of TMA manifestations, and the preservation and improvement of the function of the affected organs. Long-term experience with eculizumab has demonstrated its superior efficacy by dramatically improving the prognosis of renal function recovery in aHUS patients.